Developmental Therapeutics Program
Developmental Therapeutics Program
批准号:
8388368
负责人:
FRANK PATRICK MCCORMICK
金额:
$0.01万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-08-05 至 2017-05-31
关键词:
1-Phosphatidylinositol 3-KinaseApoptosisAreaBiochemistryBiological ModelsBreastBudgetsCancer Center Support GrantCell CycleClinicClinical OncologyClinical SciencesClinical TrialsClinical Trials UnitCollaborationsComplementComprehensive Cancer CenterDNA biosynthesisDevelopmental Therapeutics ProgramDiseaseEnzymesEvolutionFamilyFosteringGeneticGenetic DeterminismGenomeGoalsGrantHematopoietic NeoplasmsHistone DeacetylaseIndividualJournalsMAP Kinase GeneMalignant NeoplasmsMalignant neoplasm of prostateMedicineNatureNeurologic OncologyNew EnglandPathway interactionsPatientsPeer ReviewPharmaceutical PreparationsPharmacogenomicsPhasePhase I Clinical TrialsPhase II Clinical TrialsPhosphotransferasesPhysiciansPopulation SciencesPre-Clinical ModelPreclinical TestingProtocols documentationPublicationsReceptor Protein-Tyrosine KinasesResearchResearch ActivityResearch PersonnelResistanceScientistSignal TransductionSignal Transduction PathwayTelomeraseTestingTranslatingTranslationsUnited States National Academy of SciencesValidationWorkangiogenesisbasebioimagingchromatin remodelingdesigndrug discoveryinnovationinterestmembermolecular pathologynoveloncologyoncology programpre-clinical researchprogramstechnology developmenttherapeutic targettreatment strategy
中文摘要
发育治疗学项目是从更基本的细胞周期和信号传导项目演变而来的,
在海伦·迪勒家庭综合癌症中心之前的更新周期中,
支助赠款。细胞周期和信号传导计划的研究主题与识别有关
和治疗靶点的验证。其中许多靶标随后进入临床前测试
或者准备在早期临床试验中探索。新的早期临床试验部门已经创建了
一个理想的机会,有效地翻译这些主题,通过设计和分析的创新
研究协议。该计划由32名成员组成,涉及13个不同的部门,
将基础癌症生物学家和医生科学家聚集在一起,共同目标是发现和测试
癌症的新化合物和治疗策略该计划的主题是:
1)靶向信号转导途径(RTK、RAS、RAF/MAPK、PI 3'激酶和wnt)
2)靶向DNA复制和基因组完整性(细胞周期、端粒酶、HDAC)
3)血管生成
4)凋亡
5)敏感性和抗性的遗传决定因素
该计划成员的广泛专业知识将相互丰富和补充的发现,
个体研究者,总体计划目标是加速从药物发现到
更有效、毒性更低的癌症药物的批准。
该计划的研究范围从药物发现,细胞信号传导,分子病理学和生物成像,
药物基因组学,以及临床和人口科学与最近的高影响力出版物在自然,
自然医学,自然遗传学,新英格兰医学杂志,临床肿瘤学杂志,杂志
生物化学,JAMA,美国国家科学院院刊,和
《柳叶刀》该方案在方案内和方案间的比例相当大,而且不断增加。
出版物,反映了工作的专题广度和新出现的战略整合努力
的成员。在上一个预算年度,该方案共获得7,271,609美元的同行审议支助。的
计划有12%的计划内出版物和13%的计划间出版物。
英文摘要
The Developmental Therapeutics Program evolved from the more basic Cell Cycling and Signaling Program,
which scored "Outstanding" in prior renewal cycles ofthis Helen Diller Family Comprehensive Cancer Center
support grant. The research themes ofthe Cell Cycling and Signaling Program were related to identification
and validation of therapeutic targets. Many of these targets have subsequently moved into preclinical testing
or are ready to be explored in early-stage clinical trials. The new Eariy Phase Clinical Trials Unit has created
an ideal opportunity to translate these themes effectively, through the design and analysis of innovative
research protocols. The Program comprises 32 members involving 13 different departments and brings
together basic cancer biologists and physician scientists with the common goal of discovering and testing
novel compounds and treatment strategies for cancer The Program themes are:
1) Targeting signal transduction pathways (RTKs, RAS, RAF/MAPK, Pl 3' kinase, and wnt)
2) Targeting DNA replication and genome integrity (cell cycle, telomerase, HDAC)
3) Angiogenesis
4) Apoptosis
5) Genetic determinants of sensitivity and resistance
The wide range of expertise ofthe Program members will mutually enrich and complement the discoveries of
individual investigators with the overall Program goal being to accelerate the transition from drug discovery
to the approval of more effective and less toxic drugs for patients with cancer.
Research in the Program spans from drug discovery, cell signaling, molecular pathology and bioimaging to
pharmacogenomics, as well as clinical and population science with recent high impact publications in Nature,
Nature Medicine, Nature Genetics, New England Journal of Medicine, Journal of Clinical Oncology, Journal
of Biological Chemistry, JAMA, Proceedings of the National Academy of Science of the United States, and
The Lancet. The Program has a sizable and increasing percentage of intra- and inter-programmatic
publications, which reflect the thematic breadth of the work and the emerging efforts of strategic integration
of its members. The Program had $7,271,609 total peer-reviewed support for the last budget year. The
Program has 12% intra-programmatic and 13% inter-programmatic publications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biodesy Delta System for San Francisco Bay Area Region
-
批准号:9273813
-
项目类别:
-
资助金额:$60.0万
-
财政年份:2017
-
负责人:FRANK PATRICK MCCORMICK
-
依托单位:
New Ways of Targeting K-Ras
-
批准号:9889906
-
项目类别:
-
资助金额:$94.43万
-
财政年份:2016
-
负责人:FRANK PATRICK MCCORMICK
-
依托单位:
New Ways of Targeting K-Ras
-
批准号:10381482
-
项目类别:
-
资助金额:$92.23万
-
财政年份:2016
-
负责人:FRANK PATRICK MCCORMICK
-
依托单位:
New Ways of Targeting K-Ras
-
批准号:8956333
-
项目类别:
-
资助金额:$93.29万
-
财政年份:2016
-
负责人:FRANK PATRICK MCCORMICK
-
依托单位:
Breast Oncology
-
批准号:8710509
-
项目类别:
-
资助金额:$7.49万
-
财政年份:2013
-
负责人:FRANK PATRICK MCCORMICK
-
依托单位:
Bay Area Cancer Target Discovery and Development Network
-
批准号:8676480
-
项目类别:
-
资助金额:$78.75万
-
财政年份:2012
-
负责人:FRANK PATRICK MCCORMICK
-
依托单位:
Bay Area Cancer Target Discovery and Development Network
-
批准号:8464683
-
项目类别:
-
资助金额:$76.95万
-
财政年份:2012
-
负责人:FRANK PATRICK MCCORMICK
-
依托单位:
Bay Area Cancer Target Discovery and Development Network
-
批准号:8323024
-
项目类别:
-
资助金额:$79.48万
-
财政年份:2012
-
负责人:FRANK PATRICK MCCORMICK
-
依托单位:
Bay Area Cancer Target Discovery and Development Network
-
批准号:8892113
-
项目类别:
-
资助金额:$81.11万
-
财政年份:2012
-
负责人:FRANK PATRICK MCCORMICK
-
依托单位:
ID OF EFFECTORS FOR RAS FAMILY GTPASES & ELUCIDATION OF MECHANISM OF ACTION
-
批准号:8363750
-
项目类别:
-
资助金额:$0.35万
-
财政年份:2011
-
负责人:FRANK PATRICK MCCORMICK
-
依托单位:
REGULATION OF RAS/MAPK SIGNALLING BY SPREDL AND RELATED PROTEINS
-
批准号:8363792
-
项目类别:
-
资助金额:$0.93万
-
财政年份:2011
-
负责人:FRANK PATRICK MCCORMICK
-
依托单位:
ROLE OF CD133 IN TUMORIGENESIS
-
批准号:8363808
-
项目类别:
-
资助金额:$0.43万
-
财政年份:2011
-
负责人:FRANK PATRICK MCCORMICK
-
依托单位:
ISOLATION AND CHARACTERIZATION OF CELL CYCLE CHECKPOINT PROTEINS
-
批准号:8363799
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:FRANK PATRICK MCCORMICK
-
依托单位:
REGULATION OF THE RAS-RAF-MEK-ERK PATHWAY BY SPROUTY 2 AND SPROUTY 4
-
批准号:8363843
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:FRANK PATRICK MCCORMICK
-
依托单位:
ID OF NOVEL CELLULAR & VIRAL PARTNERS OF THE ADENOVIRUS L4 100K PROTEIN
-
批准号:8363764
-
项目类别:
-
资助金额:$0.01万
-
财政年份:2011
-
负责人:FRANK PATRICK MCCORMICK
-
依托单位:
ROLE OF CD133 IN TUMORIGENESIS
-
批准号:8169804
-
项目类别:
-
资助金额:$0.35万
-
财政年份:2010
-
负责人:FRANK PATRICK MCCORMICK
-
依托单位:
REGULATION OF RAS/MAPK SIGNALLING BY SPREDL AND RELATED PROTEINS
-
批准号:8169787
-
项目类别:
-
资助金额:$0.18万
-
财政年份:2010
-
负责人:FRANK PATRICK MCCORMICK
-
依托单位:
ISOLATION AND CHARACTERIZATION OF CELL CYCLE CHECKPOINT PROTEINS
-
批准号:8169795
-
项目类别:
-
资助金额:$0.18万
-
财政年份:2010
-
负责人:FRANK PATRICK MCCORMICK
-
依托单位:
ID OF NOVEL CELLULAR & VIRAL PARTNERS OF THE ADENOVIRUS L4 100K PROTEIN
-
批准号:8169758
-
项目类别:
-
资助金额:$0.18万
-
财政年份:2010
-
负责人:FRANK PATRICK MCCORMICK
-
依托单位:
ID OF EFFECTORS FOR RAS FAMILY GTPASES & ELUCIDATION OF MECHANISM OF ACTION
-
批准号:8169744
-
项目类别:
-
资助金额:$0.18万
-
财政年份:2010
-
负责人:FRANK PATRICK MCCORMICK
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: